© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
November 26, 2022
The procedures may result in temporary pressure spikes later than expected.
November 25, 2022
The therapy offers improved retinal sensitivity, visual function, as well as improvements in mobility.
November 24, 2022
Despite the latest advances in anti-VEGF therapy, a small group of patients do not achieve improved vision. Ophthalmologists are looking for options.
November 23, 2022
Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.
Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.
Investigators who are examining end-stage disease see significant visual recovery in 2 patients.
The SBL-3 ClearView clinical study, an FDA investigational device exemption clinical trial conducted at 18 sites across the US, is a prospective, subject-masked, randomized, two-arm study.
November 22, 2022
The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.
A recent study showed that only 6% of practicing ophthalmologists in the US identify as an underrepresented minority.
Oculis SA has published positive data of its licaminlimab active-controlled, multicenter, randomized, parallel-group Phase 2 clinical trial assessing the effect of topical licaminlimab on anterior chamber (AC) cell grade in patients with acute anterior uveitis.
Re-Vana Therapeutics raises $11.9 million in Series A financing for development of ophthalmic therapeutics
Harrow and iOR Partners expand national product supply agreement
OWL, WIO to co-host networking reception during Hawaiian Eye